Battleground Zero for New Alzheimer's Drug
If all three drugs fail and fail miserably the Alzheimer's community is in trouble. The pharmaceutical companies might give up. They might conclude that Alzheimer's cannot be treated effectively.
By Bob DeMarco
Alzheimer's Reading Room
The Phase 3 clinical trials for Bapineuzumab and Solanezumab are scheduled to be released in the next few months, maybe as early as next month. A third drug, Gammagard, could report next year.
Some say if the drugs fail it could be the end of Alzheimer's research as we know it. That major pharmaceutical companies might out of frustration cut back on research spending for Alzheimer's disease.
Others, like Rudolph Tanzi, Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease Harvard believe that even if the drugs fail that science is advancing. Tanzi believes that beta amyloid is "the prime therapeutic target" and that the drugs are bad, not the target. We need better drugs.